Evidence map›Paper›PMID 42506933›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2026

Virtual screening and experimental validation of a METTL3-targeting peptide with

Ying Dai, Hanying Wu, Yahui Shen, Fan Yang, Xiaohao Liu, Ting Zhuang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ying DaiDepartment of Respiratory and Critical Care Medicine, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, Jiangsu, China.
Hanying WuDepartment of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, Jiangsu, China.
Yahui ShenDepartment of Respiratory and Critical Care Medicine, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, Jiangsu, China.
Fan YangEmergency Medical Care Center, The Third Affiliated Hospital of Nanjing Medical University, Changzhou, Jiangsu, China.
Xiaohao LiuDepartment of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, Jiangsu, China.
Ting ZhuangEmergency Medical Care Center, The Third Affiliated Hospital of Nanjing Medical University, Changzhou, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The METTL3-METTL14 protein-protein interaction (PPI) plays an important role in tumour progression, and disruption of this interaction has been explored as a potential strategy. In this study, four peptides were identified from a peptide database through virtual screening and molecular docking. Among them, peptide-1 showed the lowest

Indexed as

Antineoplastic AgentsCarcinoma, Non-Small-Cell LungLung NeoplasmsMethyltransferasesPeptidesCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug Evaluation, PreclinicalDrug Screening Assays, AntitumorHumansMolecular Docking SimulationMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsMethyltransferasesMETTL3 protein, humanPeptidesBiological evaluationMETTL3–METTL14 PPInon-small cell lung cancerpeptidevirtual screening

Identifiers

PMID42506933
PMCPMC13410616

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.